

Concise Version Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

S2k-Guideline

by

Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV) In cooperation with:

Bundesverband Deutscher Pathologen e. V. (BDP)

Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG)

Deutsche Gesellschaft für Pathologie (DGP)

Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)

Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)

Deutsche Röntgengesellschaft (DRG)

Deutsche Krebsgesellschaft (DKG):

Assoziation Chirurgische Onkologie (ACO)

Arbeitsgemeinschaft Onkologische Rehabilitation und Sozialmedizin (AGORS)

Arbeitsgemeinschaft Internistische Onkologie (AIO)

Arbeitsgemeinschaft onkologische Pathologie (AOP)





Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten

DEUTSCHE RÖNTGENGESELLSCHAFT Gesellschaft für medizinische Radiologie e.V.





Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

1. Pathological classification and differentiation to other appendiceal neoplasms

Recommendation 1	
Mucinous neoplasms of the appendix should be classified according	介介
to the current WHO classification.	
Strong consensus: 100 %	

Table 1 histological criteria of mucinous neoplasms of the appendix (LAMN, HAMN and mucinous adenocarcinoma)

LAMN	HAMN	Mucinous adenocarcinoma
 Filiform or villous mucinous epithelium with tall cytoplasmic mucin vacuoles and compressed bland nuclei or epithelial undulations/ scalloping with columnar cells with nuclear pseudostratification Broad pushing margin Various degrees of extracellular mucin Fibrosis, hyalinization and calcification of the appendiceal wall 	 Features similar to LAMN with: Enlarged hyperchromatic and pleomorphic nuclei Numerous atypical mitotic features Single-cell necrosis Sloughed necrotic epithelial cells in the appendix lumen 	 Irregular or jagged glands infiltrating the wall of the appendix Extracellular mucin composing >50% of the tumour Mucin pools containing floating strips of glands or clusters of mucinous epithelial cells

Grade	Appendiceal primary	Peritoneal metastases
		Hypocellular mucin deposits
1	LAMN: low-grade cytology with pushing	Neoplastic epithelial elements with low-
I	margins	grade cytology
		No infiltrative-type invasion
		High-grade cytological features
	HAMN: high-grade cytology with	Infiltrative-type invasion characterized
2	pushing margins	by jagged or angulated glands in
2	Mucinous adenocarcinoma without	desmoplastic stroma or small mucin
	signet-ring cells	pool pattern with mucin pools
		containing clusters of tumour cells
3	Signet-ring cell adenocarcinoma with	Mucinous tumour deposits with signet-
3	signet-ring cells or infiltrating tissue	ring cells

Table 2 3-tier classification of mucinous neoplasms of the appendix and their peritoneal metastases

Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

Recommendation 2	
Low-grade appendiceal mucinous neoplasms should be classified	介介
according to the current TNM-classification.	
Strong consensus: 100 %	

Table 3 TNM-classification of LAMN and consecutive pseudomyxoma peritonei

	Definition
Tis:	Tumour confined to the appendix with acellular mucin or mucinous epithelium
115:	confined to the muscularis propria
T1	Not applicable in LAMN
T2	Not applicable in LAMN
Т3	Tumour or acellular mucin extends onto the subserosal soft tissue
T4	Tumour extends to the serosa of the appendix or mesoappendix including
17	perforation of cellular or acellular mucin
- T4a:	Tumour perforation including cellular or acellular mucin within the right lower
- 1- 1 0.	quadrant
- T4b:	Tumour invades other organs or structures
N-Status	n/a
M0	No metastatic disease
M1	Metastatic disease
M1a:	Intraperitoneal acellular mucin
M1b:	Intraperitoneal cellular mucin
M1c:	Metastases beyond the abdominal cavity

Table 4 Tumour stages of LAMN/ pseudomyxoma peritonei according to UICC

Stage	T-category	N-category	M-category
0	Tis	N0	MO
IIA	Т3	N0	MO
IIB	T4a	N0	MO
IIC	T4b	N0	MO
IVA	Every T	N0	M1a
IVA	Every T	N0	M1b G1
IVB	Every T	Every N	M1b G2, G3,Gx
IVC	Every T	Every N	M1c, every G

Recommendation 3	
Histological specimens of low-grade appendiceal mucinous	
neoplasms should be representative and the appendiceal wall should	↑↑
be captured orthograde.	
Strong consensus: 100 %	

Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

Recommendation 4	
If pseudomyxoma peritonei is present, representative embedding	
should be performed. The following can be used as a guide: 1	氜
block/cm of altered tissue.	
Strong consensus: 100 %	

Recommendation 5	
Statement: Currently, mutation analysis has no role in prognostic	
assessment and prediction of low-grade appendiceal mucinous	
neoplasms and pseudomyxoma peritonei.	
Mutation analysis can be used for the differential diagnosis of reactive	
to low-grade findings and in selected patients with unresectable	
pseudomyxoma peritonei, for the evaluation of individual tumour	⇔
therapy in accordance with the recommendations of a molecular	
multidisciplinary meeting.	
Strong consensus: 100 %	

2. Diagnostics

Recommendation 6	
If a low-grade appendiceal mucinous neoplasms/ pseudomyxoma	
peritonei is suspected preoperatively, e.g. by ultrasound findings,	
contrast-enhanced MRI abdomen-pelvis with diffusion-weighted	↑↑
imaging (especially in children and adolescents) or alternatively	
contrast-enhanced CT abdomen-pelvis should be performed.	
Strong consensus: 100 %	



In children and adolescents contrast-enhanced MRI abdomen-pelvis **should** always be performed and CT-studies should be avoided.

Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

Recommendation 7	
Statement: If a low-grade appendiceal mucinous neoplasm without	
evidence of pseudomyxoma peritonei is diagnosed postoperatively	
and adequate treatment has already been provided by surgery (see	
chapter on Therapy), no immediate staging including radiological	
imaging is indicated; this is performed later as part of surveillance (see	
chapter on Surveillance).	
To provide better comparability during further surveillance, immediate	<i>(</i>)
radiological imaging can be performed.	\Leftrightarrow
Strong consensus: 100 %	

Recommendation 8	
If a low-grade appendiceal mucinous neoplasm/ pseudomyxoma	
peritonei is suspected preoperatively, the tumour markers CEA, CA19-	^
9 and CA 125 ought to be determined in the preoperative work-up to	
differentiate from other neoplasms.	
Strong consensus: 100%	

Recommendation 9	
Screening colonoscopy to rule out synchronous colorectal neoplasms	
should be performed according the recommendations of the S3	A A
guideline "colorectal carcinoma" in patients with low-grade	氜
appendiceal mucinous neoplasms and pseudomyxoma peritonei.	
Strong consensus: 100 %	



Occurrence of LAMN in children is very rare and is mainly described in case reports. In these, no synchronous cases of colorectal cancer are reported, therefore a colonoscopy should not be performed in children.

Recommendation 10	
Instead of a surgical biopsy for histological confirmation of low-grade appendiceal mucinous neoplasms/ pseudomyxoma peritonei, treatment should be performed in the first instance (see chapter on	î
Therapy).	
Strong consensus: 100 %	

Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

3. Therapy

3.1. Perioperative phase

Recommendation 11	
All patients diagnosed with low-grade appendiceal mucinous	
neoplasms/ pseudomyxoma peritonei should be discussed in a	
multidisciplinary team meeting, who are experienced in the	介介
management of these conditions. When imaging suggests low-grade	11 11
appendiceal mucinous neoplasms/ pseudomyxoma, multidisciplinary	
discussion should be done prior to any treatment.	
Strong consensus: 100 %	

The diagnosis of LAMN/ PMP in childhood/ adolescence is very rare. To ensure appropriate evidence-based therapy, these children should be discussed in paediatric multidisciplinary team meetings and treatment should be based on these recommendations. These paediatric multidisciplinary team meetings should include: paediatric haematology/ oncology, paediatric surgery, pathology, paediatric radiology, and radiation oncology. Furthermore, it is recommended to include these patients in the registry for rare diseases in children (STEPregistry) by the Society for Paediatric Oncology/ Haematology (GPOH). Website:

https://www.gpoh.de/acl_users/login/index_html?came_from=/meldun gen/archiv/e80/umzug_des_registers_seltene_tumorerkrankungen_in_ derpaediatrie/

Given the rare occurrence of LAMN/ PMP in children, additional discussion of these cases in an adult multidisciplinary team meeting can be considered.

Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

Recommendation 12	
Patients diagnosed with low-grade appendiceal mucinous neoplasms/	
pseudomyxoma peritonei ought to be referred to/ treated in hospitals	↑
with expertise in the treatment of same.	
Statement: The following criteria appear reasonable to prove	
expertise: multidisciplinary discussion of at least 50 patients with	
malignant diseases of the peritoneum per year, and frequent	
cytoreductive surgeries and HIPEC procedures (25/year).	
Expertise can be demonstrated through publicly accredited	4
certification.	\Leftrightarrow
Strong consensus: 100 %	



Currently there is no certification/ qualification for paediatric peritoneal malignancy centres in Germany. If cytoreductive surgery, peritonectomy and HIPEC is necessary for a paediatric patient, they should be referred to hospitals that can provide experience in both paediatric surgery and visceral surgery.

Recomm	nendat	ion 13				
Patients	with	low-grade	appendiceal	mucinous	neoplasms/	俞介
pseudomyxoma peritonei should be offered psycho-oncological care.			11 11			
Strong co	nsensu	ıs: 100 %				



The occurrence of LAMN has also been described in children and adolescents. We refer to the S3 guideline "Psychosocial care in paediatric oncology and haematology" for psycho-oncological support for this patient cohort.

Recommendation 14	
If low-grade appendiceal mucinous neoplasm/ pseudomyxoma peritonei is suspected on imaging, surgical exploration and resection should be performed at a hospital with sufficient expertise (see	飰飰
Recommendation 12) after preoperative diagnostics.	
In individual cases, postponing the surgery can be considered for specific circumstances.	⇔
Strong consensus: 100 %	

Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

3.2. Treatment of locally confined LAMN

Recommendation 15	
Statement: Patients with low-grade appendiceal mucinous neoplasms	
with pTis or pT3 tumours, without evidence of extra-appendicular	
mucin (M0), corresponding to a maximum UICC stage IIa and	
complete resection with an appendicectomy (R0 status), are fully	
treated with an appendicectomy.	
Strong consensus: 100 %	

Recommendation 16	
Statement: Patients with low-grade appendiceal mucinous neoplasms	
pT4a und pT4b without evidence of extra-appendicular mucin	
beyond the right lower quadrant, and complete resection (R0 status)	
do not require a right hemicolectomy, omentectomy, parietal	
peritonectomy, or systemic treatment.	
These patients should undergo surveillance.	氜
If mucin is present on the appendiceal surface or in the right lower	
quadrant (cellular mucin or cellularity not determined), HIPEC and	
local cytoreductive surgery can be considered. The treatment decision	\Leftrightarrow
is individual and needs to be discussed with the patient.	
Strong consensus: 100 %	

Recommendation 17	
If a low-grade appendiceal mucinous neoplasm is suspected	
intraoperatively while performed an exploratory laparoscopy (i.e. for	ሱሱ
suspected appendicitis or ovarian pathology), the main goal should	氜
be to prevent intra-abdominal perforation of the neoplasm.	
If appendicectomy cannot be performed laparoscopically in a safe	ሱሱ
manner, conversion to open surgery should be performed.	们
Furthermore, the whole abdominal cavity should be inspected.	氜
Strong consensus: 100 %	

Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

3.3. Treatment of pseudomyxoma peritonei

Recommendation 18	
In patients with pseudomyxoma peritonei due to low-grade appendiceal mucinous neoplasms, complete cytoreductive surgery and HIPEC should be performed in hospitals with expertise in the	飰飰
treatment of these patients (see Recommendation 12).	
If cytoreduction without HIPEC was performed without prior knowledge of the diagnosis of pseudomyxoma peritonei secondary to low-grade appendiceal mucinous neoplasm, patients should be referred to a hospital with expertise (see Recommendation 12) for individual evaluation of HIPEC.	飰飰
Strong consensus: 100 %	

Current literature reports individual cases of children with LAMN but no cases of children with PMP. For other tumours (neuroblastoma, rhabdomyosarcoma, Wilms-tumours, desmoplastic small-round-cell tumour and others) reports of peritoneal spread with cytoreductive surgery and HIPEC is described. There is no literature reporting that children with PMP should be treated the same as adults, conversely there is no evidence that they should be treated in an alternative way.

Recommendation 19	
In the case of M1a-situation and completely resected mucin, as well as	
R0-resection at the appendix base, cytoreductive surgery and HIPEC	⇔
can be renounced.	
Strong consensus: 100 %	

Recommendation 20	
If mucin is present intraoperatively, a representative sample for	们们
histopathological evaluation should be taken.	
Strong consensus: 100 %	

Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)


Recommendation 21	
In symptomatic patients with irresectable pseudomyxoma peritonei	
(obstructive symptoms), tumour debulking can be considered.	⇔
Statement: In these cases of irresectable disease, HIPEC has not been	
proven to prolong overall survival or symptom-free survival in the	
literature.	
Strong consensus: 100 %	

Recommendation 22	
In patients with pseudomyxoma peritonei, the Sugarbaker peritoneal	
carcinomatosis index (PCI) should be calculated as well as the	氜
completeness of cytoreduction score (CC-score) after resection.	
Strong consensus: 100 %	

Table 5 Lesion size score according to Sugarbaker

Score	Definition							
0	no tumour visible							
1	tumour up to 0.5cm							
2	tumour up to 5.0cm							
3	tumour > 5.0cm or confluent							

Figure 1 Sugarbaker peritoneal carcinomatosis index, region 0 to 8



Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

 Table 5 Sugarbaker peritoneal carcinomatosis index, region 9-12

Region	Definition					
9	proximal jejunum					
10	distal jejunum					
11	proximal ileum					
12	distal ileum					

Table 7 Completeness of Cytoreduction Score

Score	Definition
CC-0	no visible tumour
CC-1	residual tumour < 2.5mm
CC-2	residual tumour 2.5mm-2.5cm
CC-3	residual tumour >2.5cm

Recommendation 23	
Patients with pseudomyxoma peritonei with involvement of the uterus	
and/or adnexal regions should be treated in cooperation with gynae-	ሱሱ
oncology. Besides oncological goals, endocrine function including	氜
preservation of fertility should be considered.	
Strong consensus: 100 %	

German registry analysis was 11 years old at time of diagnosis. Detailed information regarding children with LAMN is only described through case reports. Even though the literature regarding children with LAMN/ PMP is rare, it demonstrates that LAMN/ PMP does occur in children. Treatment of same can lead to fertility impairment. Chapter 8 of the German guideline on "Fertility counselling in oncological patients" addresses paediatric fertility. When planning treatment in these patients, advice should be sought from specialists in paediatric fertility counselling.

LAMN and PMP are rare in children but the youngest patient in a

Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

Recommendation 24	
If HIPEC is planned in patients without disease of the reproductive	
organs (regardless of gender), they should be offered fertility	↑↑
counselling prior to performing this procedure.	
Strong consensus: 100 %	

4. Surveillance

Recommendation 25	
Surveillance of patients with low-grade appendiceal mucinous	
neoplasms or pseudomyxoma peritonei ought to include tumour	ſ
markers CEA, CA 19-9 and CA 125.	
Strong consensus: 100 %	



Insertion of a cannula/ phlebotomy can induce stress or even be traumatic for children. Therefore during necessary cannula insertion for administering intravenous contrast prior to MRI, blood samples for tumour markers should be taken simultaneously. Additional phlebotomy should be prevented.

Recommendation 26	
Surveillance of patients with low-grade appendiceal mucinous	ſ
neoplasms ought to include radiological imaging.	11
If there is no contraindication, a contrast enhanced MRI of the	
abdomen and pelvis including diffusion-weighted imaging ought to	ſ
be performed.	
Alternatively a contrast-enhanced CT of the abdomen and pelvis can	<i>(</i>)
be performed.	\Leftrightarrow
Strong consensus: 100 %	



In paediatric patients, the modality of CT should not be used for surveillance of LAMN. If there are contraindications for MRI, an abdominal ultrasound should be performed by an experienced and certified sonographer.

Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

Recommendation 27	
In the follow-up of patients with low-grade appendiceal mucinous	
neoplasms/ pseudomyxoma peritonei, the importance of screening	ሱሱ
colonoscopies for early detection of colorectal carcinoma should be	氜
highlighted.	
Statement: In asymptomatic patients who are followed up post low-	
grade appendiceal mucinous neoplasm/pseudomyxoma peritonei,	
there is no evidence to support screening colonoscopies before the	
age of 50.	
Strong consensus: 100 %	

Recommendation 28	
Surveillance for low-grade appendiceal mucinous neoplasms or	
pseudomyxoma peritonei ought to be performed for 5 years in six-	ſ
monthly intervals.	
In individual cases, surveillance can be prolonged.	\Leftrightarrow
Strong consensus: 100 %	

Table 6 Surveillance-Regimen

Months	6	12	18	24	30	36	42	48	54	60
Imaging*	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Tumour markers**	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х

* MRI abdomen/pelvis, if contraindications for an MRI are present CT abdomen/pelvis should be used. In paediatric patients with contraindications for MRI, ultrasound ought to be performed ** CEA, CA 19-9, CA 125

Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

Guideline coordination:

Dr. med. Franziska Köhler Klinik und Poliklinik für Allgemein-, Viszeral-, Transplantations-, Gefäß- und Kinderchirurgie Universitätsklinik Würzburg Oberdürrbacherstr. 6 97080 Würzburg <u>Koehler F2@ukw.de</u>

Prof. Dr. med. Armin Wiegering Klinik und Poliklinik für Allgemein-, Viszeral-, Transplantations-, Gefäß- und Kinderchirurgie Universitätsklinik Würzburg Oberdürrbacherstr. 6 97080 Würzburg <u>Wiegering A@ukw.de</u>



The symbol on the left highlights recommendations and statements that are specifically for children, or explains how recommendations should be implemented in this cohort

List of Abbreviations		
CA 125	Cancer Antigen 125	
CA 19-9	Carbohydrate Antigen 19-9	
CC-Score	Completeness of Cytoreduction Score	
CEA	Carcinoembryonic antigen	
СТ	Computed tomography	
HAMN	high-grade appendiceal mucinous neoplasm	
HIPEC	Hyperthermic intraperitoneal chemotherapy	
CRC	Colorectal carcinoma	
LAMN	Low-grade appendiceal mucinous neoplasm	
PCI	Sugarbaker peritoneal carcinomatosis index	
PMP	Pseudomyxoma peritonei	
UICC	Union for International Cancer Control	
WHO	World Health Organization	

Concise Version Diagnostics, Treatment and Surveillance of Low-Grade Appendiceal Mucinous Neoplasms (LAMN)

Versionsnummer:	1.0
Erstveröffentlichung:	2024/02/01
Nächste Überprüfung geplant:	2029/01/31

Die AWMF erfasst und publiziert die Leitlinien der Fachgesellschaften mit größtmöglicher Sorgfalt – dennoch kann die AWMF für die Richtigkeit des Inhalts keine Verantwortung übernehmen. **Insbesondere bei Dosierungsangaben sind stets die Angaben der Hersteller zu beachten!**

Autorisiert für elektronische Publikation: AWMF online